Tusk Therapeutics Information

Tusk Therapeutics is focussed on developing medicines with the ability to harness the power of the immune system to fight cancer. We have established a diversified pipeline of antibodies against a selection of both novel and validated targets that play an important role in the immune response. We are pursuing multiple programs that focus on the modulation, activation or depletion of immune cell populations in the tumour microenvironment to generate a potent anti-cancer effect. Tusk is uniquely positioned to become a leading scientific and clinical company within the immuno oncology field through: ​•an in-depth understanding of the innate and the adaptive immune system. •an established immune profiling and immune biology platform for evaluation of antibodies •strategic partnerships and licensing agreements with top research institutes •a portfolio of multiple promising immune-modulating antibodies and a strong IP position •an experienced management team, with top-level scientific advisors and board of directors. The Company is headquartered in Stevenage, Greater London/Cambridge Area, United Kingdom.